Compare Sana Biotechnology Inc (SANA) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Warner Music Group Corp — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $947.48M), while Warner Music Group Corp trades at $28.16 (market cap $14.73B). The key difference: Warner Music Group Corp is far larger — about 15.5× Sana Biotechnology Inc's market cap, and Warner Music Group Corp pays a 2.84% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | WMG | |
|---|---|---|
Market Cap | $947.48M | $14.73B |
Sector | Health | Media |
52-Week High | $5.92 | $34.72 |
52-Week Low | $2.68 | $23.65 |
Enterprise Value | $860.73M | $19.03B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Warner Music Group (WMG) trades at $28.03, down 2.61% on the day, with a bearish technical signal. Recent quarterly earnings show mixed results, with Q1 and Q2 2026 beats but a Q4 2025 miss. Revenue has grown steadily from $5.9B in 2022 to $6.7B in 2025, though net income margin declined to 5.44%. Analyst consensus is bullish with 16 buy ratings, and recent news highlights AI partnerships and licensing renewals.
Outlook is positive due to strong streaming growth and strategic AI initiatives, but risks include margin pressure and leadership changes. The stock offers value with a P/E of 22.42 and robust cash flow, though near-term volatility may persist amid market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
